CART-19 Cells For R/R B-ALL

CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.

Inclusion Criteria:

• Signed written informed consent
• Aged between 1-60 years
• Patients with relapsed/refractory B-cell ALL
• Cardiac: Left ventricular ejection fraction ≥ 50%
• Adequate renal and hepatic function
• Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

• Pregnant or lactating females.
• Any co-morbidity precluding the administration of CART-19 cells.